News - Bayer, Pricing

Filter

Current filters:

BayerPricing

Popular Filters

1 to 25 of 29 results

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo

24-03-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

UK’s NICE gives green light to Bayer’s Eylea in final guidance

26-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final guidance…

BayerEyleaNorthern EuropeOphthalmicsPharmaceuticalPricingRegulationUK

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG

Hint of minor added benefit for Bayer’s Stivarga seen by IQWiG

13-01-2014

There was a hint of positive news for German drug major Bayer, when the German Institute for Quality…

BayerGermanyNorthern EuropeOncologyPharmaceuticalPricingRegulationStivarga

Added benefit of Bayer’s Eylea again not proven, says IQWiG

Added benefit of Bayer’s Eylea again not proven, says IQWiG

08-01-2014

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

BayerEyleaGermanyNorthern EuropeOphthalmicsPharmaceuticalPricingRegulation

UK’s NICE backs second indication for Bayer’s Eylea

UK’s NICE backs second indication for Bayer’s Eylea

31-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today announced that…

BayerEuropeEyleaOphthalmicsPharmaceuticalPricingRegeneronRegulation

Modest growth forecast for global CD market

02-12-2013

The global market for cardiovascular disease - comprised of heart failure, myocardial infarction and…

AstraZenecaAZD6140BAY81-8781BayerCardio-vascularLCZ696Markets & MarketingNovartisPharmaceuticalPricingserelaxin

Bayer in settlement over Cipro pricing

04-09-2013

A partial settlement has been reached in a US class action law suit involving the prescription antibiotic…

Antibiotics and Infectious diseasesBayerCiproGenericsLegalNorth AmericaPharmaceuticalPricing

BIA warns that UK government pricing proposals would damage UK biotech

20-08-2013

The BioIndustry Association (BIA), the UK trade association for the innovative biotechnology sector,…

AvastinBayerEuropeEyleaFinancialLucentisPharmaceuticalPoliticsPricingRegeneronRoche

NICE "green light" for Bayer's Eylea as a treatment for wet AMD

31-05-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (May 31)…

BayerEuropeEyleaLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Draft guidance from NICE recommends Bayer's Xarelto for PE and DVT

19-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) this morning (April 19)…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone

19-04-2013

Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

Germany's IQWiG finds no proof of added benefit for Bayer's Eylea

22-03-2013

There was disappointment for German drug major Bayer (BAYN: DE), when the German Institute for Quality…

BayerEuropeEyleaOphthalmicsPharmaceuticalPricingRegeneronRegulation

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

09-01-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…

BayerEuropeInlytaNexavarOncologyPfizerPharmaceuticalPricingRegulation

Study attacks Pharma business practices in Brazil

11-12-2012

A study reported by broadcaster Deutsche Welle on the business practices of drug companies Bayer, Baxter…

BaxterBayerBoehringer IngelheimMarkets & MarketingPharmaceuticalPricingSouth America

Big Pharma doing more for access to medicine in developing countries than two years ago

28-11-2012

The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts…

AstraZenecaBayerGlaxoSmithKlineGlobalHealthcareJohnson & JohnsonMerck KGaAPharmaceuticalPricingResearch

Access to many more medicines in Australia, as PBS list extended

28-10-2012

More than 110,000 Australians will benefit from better access to affordable medicines following the Australian…

Asia-PacificBayerEyleaMyforticNovartisPharmaceuticalPricingRegulation

Pradaxa efficacy and cost effectiveness advantages over Xarelto

27-08-2012

Indirect comparison based on the RE-LYtrial (for family owned German drugmaker Boehringer Ingelheim's…

BayerBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingResearchXarelto

UK NICE says final "yes" for Bayer's Xarelto to treat blood clots

24-07-2012

Confirming its final draft guidance last month (The Pharma Letter June 1), in final guidance published…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF

01-06-2012

In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

"NICE" news for Bayer, as UK watchdog backs Xarelto for AF

23-05-2012

There was good news today (May 23) for German drug major Bayer (BAYN: DE), when the UK's drug watchdog,…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

1 to 25 of 29 results

Back to top